摘要
目的探究抑郁症患者应用阿戈美拉汀+文拉法辛治疗的临床效果及治疗安全性。方法选取274例抑郁症患者作为研究对象,以随机数字表法分为对照组和观察组,各137例。对照组予以阿戈美拉汀口服治疗,观察组在对照组基础上联合文拉法辛缓释片口服治疗。比较两组患者治疗效果,不同治疗时间汉密尔顿抑郁量表(HAMD)评分,不良反应发生情况。结果观察组治疗总有效率为97.81%,高于对照组的91.24%,差异具有统计学意义(P<0.05)。治疗前及治疗2周时,两组HAMD评分比较差异无统计学意义(P>0.05);治疗4、6周时,观察组HAMD评分均低于对照组,差异具有统计学意义(P<0.05)。观察组不良反应发生率为7.30%,与对照组的4.38%比较差异无统计学意义(P>0.05)。结论在抑郁症治疗中,应用阿戈美拉汀+文拉法辛治疗,可提升治疗效果,改善患者抑郁状态,且治疗安全性理想,具深入研究价值。
Objective To investigate the clinical effect and safety of agomelatine combined with venlafaxine in the treatment of depression.Methods A total of 274 patients with depression were studied and divided into control group and observation group by random numerical table,with 137 cases in each group.The control group was treated with oral administration of agomelatine,and the observation group was treated with oral administration of venlafaxine sustained-release tablets on the basis of the control group.The therapeutic effects,Hamilton Depression Scale(HAMD)scores at different treatment time points,and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 97.81%,which was higher than 91.24%in the control group,and the difference was statistically significant(P<0.05).Before treatment and after 2 weeks of treatment,there was no statistically significant difference in HAMD scores between the two groups(P>0.05).At 4 and 6 weeks of treatment,HAMD scores of the observation group were lower than those of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 7.30%,which was not statistically different from 4.38%in the control group(P>0.05).Conclusion In the treatment of depression,the application of agomelatine and venlafaxine can improve the therapeutic effect and the depression state of patients,and the safety of treatment is ideal,which has the value of in-depth study.
作者
齐龙涛
QI Long-tao(Department of Psychiatry,Third Affiliated Hospital of Shenyang Medical College(Shenyang 242 Hospital),Shenyang 110034,China)
出处
《中国现代药物应用》
2021年第21期175-178,共4页
Chinese Journal of Modern Drug Application